The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis

The World Health Organization (WHO) estimates that 9.6 million cases of tuberculosis (TB) occurred in 2014 (corresponding to 133 cases per 100 000 population) with 1.5 million deaths [1]. Furthermore, 3.3% of new and 20% of previously treated cases harbour multidrug-resistant (MDR)-TB strains. Eastern European and central Asian countries still have the highest prevalence of MDR-TB. In low TB incidence countries (largely covering North America and Western Europe; figure 1) 155 000 TB cases occur every year with over 10 000 deaths [2]. Updated clinical practice guidelines on TB treatment provide clinical and public health management recommendations http://ow.ly/FDcN302Jdmp

[1]  R. Chaisson,et al.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Mamta B. Singh,et al.  Corticosteroids for managing tuberculous meningitis , 2016, The Cochrane database of systematic reviews.

[3]  Christopher Gilpin,et al.  WHO's new End TB Strategy , 2015, The Lancet.

[4]  G. Marks,et al.  The impact of sputum quality on tuberculosis diagnosis: a systematic review. , 2015, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  Francesco Castelli,et al.  Towards tuberculosis elimination: an action framework for low-incidence countries , 2015, European Respiratory Journal.

[6]  Jann-Yuan Wang,et al.  Optimal duration of anti-TB treatment in patients with diabetes: nine or six months? , 2015, Chest.

[7]  C. Leung,et al.  Smoking adversely affects treatment response, outcome and relapse in tuberculosis , 2014, European Respiratory Journal.

[8]  A. Crook,et al.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.

[9]  R. Chaisson,et al.  Immunotherapy for tuberculous pericarditis. , 2014, The New England journal of medicine.

[10]  A. Benedetti,et al.  Evidence-based, agreed-upon health priorities to remedy the tuberculosis patient's economic disaster , 2014, European Respiratory Journal.

[11]  John T Brooks,et al.  Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Jae Seung Lee,et al.  Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. , 2014, Respiratory medicine.

[13]  D. Havlir,et al.  Tuberculosis Immune Reconstitution Inflammatory Syndrome in A5221 STRIDE: Timing, Severity, and Implications for HIV–TB Programs , 2014, Journal of acquired immune deficiency syndromes.

[14]  A. Sandgren,et al.  The European Union standards for tuberculosis care: do they need an update? , 2014, European Respiratory Journal.

[15]  K. Fielding,et al.  An Evaluation of Culture Results during Treatment for Tuberculosis as Surrogate Endpoints for Treatment Failure and Relapse , 2013, PloS one.

[16]  J. Critchley,et al.  Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. , 2013, The Lancet. Infectious diseases.

[17]  A. Benedetti,et al.  An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  V. Leimane,et al.  European Union Standards for Tuberculosis Care , 2012, European Respiratory Journal.

[19]  K. Kliiman,et al.  TB and MDR/XDR-TB in European Union and European Economic Area countries: managed or mismanaged? , 2012, European Respiratory Journal.

[20]  R. Granich,et al.  Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. , 2012, Bulletin of the World Health Organization.

[21]  D. Mitchison,et al.  The chemotherapy of tuberculosis: past, present and future. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[22]  A. Harries,et al.  The impact of diabetes on tuberculosis treatment outcomes: A systematic review , 2011, BMC medicine.

[23]  J. Farrar,et al.  Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  G. Maartens,et al.  Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome , 2010, AIDS.

[25]  K. Steingart,et al.  Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. , 2010, The Lancet. Infectious diseases.

[26]  R. Verma,et al.  Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis , 2009, Annals of tropical medicine and parasitology.

[27]  A. Benedetti,et al.  Standardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis , 2009, PLoS medicine.

[28]  A. Benedetti,et al.  Effect of Duration and Intermittency of Rifampin on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis , 2009, PLoS medicine.

[29]  P. Reiss,et al.  Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. , 2008, The Lancet. Infectious diseases.

[30]  Alimuddin Zumla,et al.  Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial , 2008, BMJ : British Medical Journal.

[31]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[32]  Dermot Maher,et al.  International standards for tuberculosis care. , 2006, The Lancet. Infectious diseases.

[33]  H. Reuter,et al.  Experience with adjunctive corticosteroids in managing tuberculous pericarditis. , 2006, Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners.

[34]  Michael K Gould,et al.  An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. , 2006, American journal of respiratory and critical care medicine.

[35]  T. Sterling,et al.  Lack of weight gain and relapse risk in a large tuberculosis treatment trial. , 2006, American journal of respiratory and critical care medicine.

[36]  A. Tunkel.  Dexamethasone for treatment of tuberculous meningitis in adolescents and adults , 2005, Current infectious disease reports.

[37]  S. Ho,et al.  A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. , 2004, American journal of respiratory and critical care medicine.

[38]  T. Bell.  [Treatment of tuberculosis-disease]. , 2004, Medecine et maladies infectieuses.

[39]  T. Hodge,et al.  Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. , 2003, American journal of respiratory and critical care medicine.

[40]  Charles L Daley,et al.  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. , 2003, American journal of respiratory and critical care medicine.

[41]  American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis , 2002 .

[42]  R. Chaisson,et al.  Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial , 2002, The Lancet.

[43]  S. Siziya,et al.  Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients , 2000, Heart.

[44]  L. Clancy,et al.  Tuberculosis management in Europe. Task Force of the European Respiratory Society (ERS), the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) Europe Region. , 1999, The European respiratory journal.

[45]  D. Mitchison,et al.  Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[46]  J. Karon,et al.  Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial , 1999, The Lancet.

[47]  D. Dooley,et al.  Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  P. Donald,et al.  Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. , 1997, Pediatrics.

[49]  Y. Thavornpitak,et al.  Corticosteroid in tuberculous meningitis. , 1996, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[50]  M. Behari,et al.  Randomized controlled trial of dexamethasone in tuberculous meningitis. , 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[51]  D. Mitchison.  Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. , 1993, The American review of respiratory disease.

[52]  Y. Sultan,et al.  Dexamethasone adjunctive treatment for tuberculous meningitis. , 1991, The Pediatric infectious disease journal.

[53]  D. Girling,et al.  CONTROLLED CLINICAL TRIAL OF COMPLETE OPEN SURGICAL DRAINAGE AND OF PREDNISOLONE IN TREATMENT OF TUBERCULOUS PERICARDIAL EFFUSION IN TRANSKEI , 1988, The Lancet.

[54]  D. Girling,et al.  CONTROLLED TRIAL OF PREDNISOLONE AS ADJUVANT IN TREATMENT OF TUBERCULOUS CONSTRICTIVE PERICARDITIS IN TRANSKEI , 1987, The Lancet.

[55]  Z. Farid,et al.  The use of dexamethasone in preventing ocular complications in tuberculous meningitis. , 1983, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[56]  M. Zierski,et al.  Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study. , 1980, Tubercle.

[57]  A. Nunn,et al.  [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy]. , 1978, Bulletin of the International Union against Tuberculosis.

[58]  V. R. Aber,et al.  Chimiothérapie de courte durée de la tuberculose. Facteurs de rechute dans la chimiothérapie de courte durée. , 1978 .

[59]  J. Escobar,et al.  Mortality from tuberculous meningitis reduced by steroid therapy. , 1975, Pediatrics.

[60]  M. K. Mukherjee,et al.  Dexamethasone in tuberculous meningitis. Relationship of cerebrospinal fluid effects to therapeutic efficacy. , 1969, Annals of internal medicine.

[61]  M. Ashby,et al.  Tuberculous meningitis treated with cortisone. , 1955, Lancet.